Zacks Investment Research lowered shares of Dermira, Inc. (NASDAQ:DERM) from a hold rating to a sell rating in a research note published on Thursday.

According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Cantor Fitzgerald reiterated a buy rating and issued a $45.00 target price on shares of Dermira in a research note on Monday, November 6th. Mizuho reiterated a buy rating and issued a $43.00 target price (up from $40.00) on shares of Dermira in a research note on Thursday, September 7th. Leerink Swann reiterated an outperform rating and issued a $41.00 target price (down from $47.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, BidaskClub downgraded shares of Dermira from a hold rating to a sell rating in a research note on Wednesday, August 2nd. Five equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $43.33.

Dermira (DERM) opened at $24.81 on Thursday. Dermira has a 1-year low of $21.35 and a 1-year high of $38.75. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/dermira-inc-derm-rating-lowered-to-sell-at-zacks-investment-research/1699876.html.

In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $27.52, for a total transaction of $137,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eugene A. Bauer sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $30.04, for a total transaction of $225,300.00. The disclosure for this sale can be found here. Insiders have sold 29,400 shares of company stock valued at $822,553 over the last 90 days. Company insiders own 13.30% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its position in Dermira by 6.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 149,991 shares of the biopharmaceutical company’s stock worth $4,050,000 after acquiring an additional 9,496 shares during the last quarter. Wells Fargo & Company MN lifted its position in Dermira by 4.0% during the third quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock worth $1,431,000 after acquiring an additional 2,025 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in Dermira by 11.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 32,910 shares of the biopharmaceutical company’s stock worth $889,000 after acquiring an additional 3,302 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in Dermira during the third quarter worth approximately $2,689,000. Finally, SG Americas Securities LLC lifted its position in Dermira by 47.7% during the third quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 2,627 shares during the last quarter. Hedge funds and other institutional investors own 98.09% of the company’s stock.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.